Forging Smarter Clinical CRO Partnerships

Trial design, recruitment, and supply chains represent pain points that routinely derail timelines and budgets for sponsors. There are, however, ways that emerging biotechs can get more speed, rigor, and strategic value from their relationships with clinical contract research organizations. REV Clinical uses rigorous upfront feasibility, pre qualified high performing sites, and real time data oversight to enable faster study start up without sacrificing quality. Fairooz Kabbinavar, Chief Medical Officer at REV Clinical, offers advice on where lean biotechs should never cut corners, how to spot red flags in prospective CRO partners, and why “follow the science” remains the best operating principle when capital is scarce but expectations from regulators and investors keep rising.

‍